By Iain Gilbert
Date: Thursday 26 Feb 2026
(Sharecast News) - Ingredients business Tate & Lyle traded lower early on Thursday after the group reiterated that both full‑year revenue and underlying earnings were still expected to decline, with muted market demand continuing to weigh on pro forma sales.
| Director/PDMR Shareholding | 18-Dec-2025 | ShareCast |
| Tate & Lyle talks up CP Kelco synergies after we... | 06-Nov-2025 | ShareCast |
| Tate & Lyle sinks on revenue and earnings warning | 01-Oct-2025 | ShareCast |
| Morgan Stanley downgrades Tate & Lyle, shares sl... | 22-Sep-2025 | ShareCast |
| Director dealings: Tate and Lyle CFO snaps up sh... | 28-May-2025 | ShareCast |
| Holding(s) in Company | 13-Mar-2026 | 16:00 | RNS |
| Holding(s) in Company | 02-Mar-2026 | 14:00 | RNS |
| Trading Statement | 26-Feb-2026 | 07:00 | RNS |
| Holding(s) in Company | 23-Feb-2026 | 10:00 | RNS |
| Directorate change | 21-Jan-2026 | 07:00 | RNS |
| Questor : Tate & Lyle | 02-Jun-2011 | Telegraph |
| Questor :Tate & Lyle | 03-Feb-2011 | Telegraph |
| Investment Column : Tate & Lyle | 05-Nov-2010 | The Independent |
| Questor: Tate & Lyle | 09-Nov-2009 | Sunday Telegraph |
| FTSE latest: BA, RBS up; Rentokil down | 06-Nov-2009 | Daily Mail |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 331.60p |
| Change Today | -25.80p |
| % Change | -7.22 % |
| 52 Week High | 603.50 |
| 52 Week Low | 331.00 |
| Volume | 1,779,704 |
| Shares Issued | 445.45m |
| Market Cap | £1,477.10m |
| RiskGrade | 93 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 5 |
| Buy | 3 |
| Neutral | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 14 |

| Latest | Previous | |
|---|---|---|
| Interim | Final | |
| Ex-Div | 20-Nov-25 | 19-Jun-25 |
| Paid | 05-Jan-26 | 01-Aug-25 |
| Amount | 6.60p | 13.40p |
| Time | Volume / Share Price |
| 15:07 | 2 @ 334.40p |
| 14:27 | 2 @ 335.80p |
| 16:35 | 3,975 @ 331.60p |
| 16:35 | 631,990 @ 331.60p |
| 16:35 | 1 @ 331.60p |
| CEO | Nick Hampton |
| Chair | David Hearn |
| CFO | Sarah Kuijlaars |
You are here: research